Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate

Table 2 Role of probiotics in inflammatory bowel diseases

Ref.	No. (intervention/control)	Probiotic	Control	Results
Remission induction in UC
Kato et al[68]	20 (10/10)	B. breve, B. bifidum, L. acidophilus + 5ASA/SASP	Placebo	slight ↑
Tursi et al[69]	90 (30/60)	VSL#3 + balsalazide	Balsalazide alone	↑
			5ASA
Miele et al[70]	29 (14/15)	VSL#3	Placebo	↑
Sood et al[71]	147 (77/70)	VSL#3	Placebo	↑
Matthes et al[72]	57 (46/11)	E. coli Nissle 1917	Placebo	↑
Tursi et al[73]	144 (71/73)	VSL#3	Placebo	↑
Maintenance of remission
Kruis et al[74]	103 (50/53)	E. coli Nissle 1917	5ASA	Similar efficacy
Kruis et al[75]	327 (162/165)	E. coli Nissle 1917	5ASA	Similar efficacy
Zocco et al[76]	187 (127/60)	Lactobacillus GG	5ASA	Similar efficacy (LGG more effective than 5ASA alone in prolonging relapse free time)
		Lactobacillus GG + 5ASA
Miele et al[70]	29 (14/15)	VSL#3	Placebo	↑
Wildt et al[77]	32 (20/12)	L. acidophilus La5, B. animalis subs P. lactis BB-12	Placebo	Similar effect
Maintenance of remission in Pouchitis
Gionchetti et al[78]	40 (crossover)	VSL#3	Placebo	↑
Gionchetti et al[79]	40 (20/20)	VSL#3	Placebo	↑
Mimura et al[80]	36 (20/16)	VSL#3	Placebo	↑
Maintenance of remission in CD
Prantera et al[81]	45 (23/22)	Lactobacillus GG	Placebo	Similar effect
Bousvaros et al[82]	75 (39/36)	Lactobacillus GG	placebo	Similar effect
Raju et al[83]	90 (43/47)	L. johnsonii	placebo	Similar effect
Van Gossum et al[84]	70 (34/36)	L. johnsonii	placebo	Similar effect
Induction of remission in CD
Steed et al[85]	24 (13/11)	B. longum, Synergy 1 + conventional therapy	Placebo + conventional therapy	Similar effect

All article are randomized controlled trials. 5ASA: Mesalazine; UC: Ulcerative colitis; CD: Crohn’s disease.